Biosyent Stock Price, News & Analysis (CVE:RX)

C$9.46 -0.03 (-0.32 %)
(As of 01/22/2018 03:16 AM ET)
Previous CloseC$9.49
Today's RangeC$9.32 - C$9.64
52-Week RangeC$6.90 - C$11.00
Volume2,104 shs
Average Volume3,946 shs
Market CapitalizationC$137.12 million
P/E Ratio28.67
Dividend YieldN/A

About Biosyent (CVE:RX)

BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of papillary non-muscle invasive bladder cancer. The company’s products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; and endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, it manufactures and markets Protect-It, a non-chemical and food-safe grain insecticide used as a preventative treatment against insect infestations in stored grains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 1947 and is headquartered in Toronto, Canada.

Receive RX News and Ratings via Email

Sign-up to receive the latest news and ratings for RX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio28.6666666666667
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSC$0.33
Net IncomeN/A
Net Margins23.96%
Return on Equity25.90%
Return on Assets23.21%


Outstanding Shares14,491,000

Biosyent (CVE:RX) Frequently Asked Questions

What is Biosyent's stock symbol?

Biosyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."

How were Biosyent's earnings last quarter?

Biosyent Inc. (CVE:RX) released its earnings results on Wednesday, November, 15th. The company reported $0.09 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.10 by $0.01. Biosyent had a return on equity of 25.90% and a net margin of 23.96%. View Biosyent's Earnings History.

When will Biosyent make its next earnings announcement?

Biosyent is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for Biosyent.

Who are some of Biosyent's key competitors?

Who are Biosyent's key executives?

Biosyent's management team includes the folowing people:

  • Rene C. Goehrum, Chairman of the Board, President, Chief Executive Officer
  • Alfred D'Souza, Chief Financial Officer
  • Kevin Wilson, Vice President - Sales and Marketing of BioSyent Pharma Inc
  • Larry Andrews, Director
  • Sara Elford, Director
  • Peter D. Lockhard, Independent Director
  • Paul R. Montador, Independent Director
  • Stephen Wilton, Independent Director

How do I buy Biosyent stock?

Shares of Biosyent and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Biosyent's stock price today?

One share of Biosyent stock can currently be purchased for approximately C$9.46.

How big of a company is Biosyent?

Biosyent has a market capitalization of C$137.12 million.

How can I contact Biosyent?

Biosyent's mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The company can be reached via phone at +1-905-2060013.

MarketBeat Community Rating for Biosyent (RX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Biosyent and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biosyent (CVE:RX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Biosyent (CVE:RX) Consensus Price Target History

Price Target History for Biosyent (CVE:RX)

Biosyent (CVE:RX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
2/13/2017Bloom BurtonReiterated RatingAccumulateView Rating Details
(Data available from 1/22/2016 forward)


Biosyent (CVE:RX) Earnings History and Estimates Chart

Earnings by Quarter for Biosyent (CVE:RX)

Biosyent (CVE RX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2017Q3 2017C$0.10C$0.09ViewN/AView Earnings Details
8/16/2017Q2 2017C$0.09C$0.11ViewN/AView Earnings Details
5/25/2017Q1 2017C$0.08C$0.06C$4.80 millionC$3.82 millionViewN/AView Earnings Details
3/15/2017Q4 2016C$0.07C$0.08ViewN/AView Earnings Details
11/23/2016Q3 2016C$0.08C$0.08ViewN/AView Earnings Details
8/12/2016Q2 2016C$0.07ViewN/AView Earnings Details
5/27/2016Q1 2016C$0.07ViewN/AView Earnings Details
3/4/2016Q4 2015C$0.05C$0.05ViewN/AView Earnings Details
11/11/2015Q3 2015C$0.08C$0.08ViewN/AView Earnings Details
8/12/2015Q2 2015C$0.07C$0.06ViewN/AView Earnings Details
5/13/2015Q1 2015C$0.05C$0.07ViewN/AView Earnings Details
2/25/2015Q4 2014C$0.04C$0.05ViewN/AView Earnings Details
10/20/2014Q3 2014C$0.07ViewN/AView Earnings Details
8/21/2014Q2 2014C$0.06ViewN/AView Earnings Details
5/16/2014Q1 2014C$0.04ViewN/AView Earnings Details
3/12/2014Q4 2013C$0.04ViewN/AView Earnings Details
11/20/2013Q3 2013C$0.04ViewN/AView Earnings Details
8/22/2013Q2 2013C$0.03ViewN/AView Earnings Details
5/22/2013Q1 2013C$0.03ViewN/AView Earnings Details
3/21/2013Q4 2012C$0.04ViewN/AView Earnings Details
11/15/2012Q3 2012C$0.03ViewN/AView Earnings Details
8/22/2012Q2 2012C$0.03ViewN/AView Earnings Details
5/22/2012Q1 2012C$0.02ViewN/AView Earnings Details
3/29/2012Q4 2011C$0.01ViewN/AView Earnings Details
3/14/2011Q4 2010C$0.01ViewN/AView Earnings Details
11/24/2010Q3 2010C$0.01ViewN/AView Earnings Details
8/17/2010Q2 2010C($0.01)ViewN/AView Earnings Details
11/30/2009Q3 2009C$0.01ViewN/AView Earnings Details
8/28/2009Q2 2009C($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Biosyent (CVE:RX) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Biosyent (CVE:RX)

No dividend announcements for this company have been tracked by

Insider Trades

Biosyent (CVE RX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Biosyent (CVE:RX)

Biosyent (CVE RX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2017Peter Douglas LockhardDirectorSell500C$10.30C$5,150.00
12/1/2017Douglas Robert LarsonDirectorSell800C$10.50C$8,400.00
11/23/2017Peter Douglas LockhardDirectorSell500C$10.20C$5,100.00
9/18/2017Douglas Robert LarsonDirectorSell1,300C$9.25C$12,025.00
9/15/2017Douglas Robert LarsonDirectorSell200C$9.25C$1,850.00
9/14/2017Douglas Robert LarsonDirectorSell1,500C$9.20C$13,800.00
6/21/2017Douglas Robert LarsonDirectorSell1,000C$8.10C$8,100.00
6/19/2017Douglas Robert LarsonDirectorSell100C$8.05C$805.00
6/16/2017Milt WakefieldDirectorSell1,000C$7.98C$7,980.00
6/13/2017Milt WakefieldDirectorSell2,000C$7.92C$15,840.00
6/12/2017Douglas Robert LarsonDirectorSell200C$8.05C$1,610.00
6/8/2017Milt WakefieldDirectorSell2,000C$7.93C$15,860.00
6/6/2017Milt WakefieldDirectorSell2,000C$7.74C$15,480.00
6/2/2017Milt WakefieldDirectorSell2,000C$7.80C$15,600.00
3/31/2017Douglas Robert LarsonDirectorSell900C$7.75C$6,975.00
3/23/2017Kevin WilsonInsiderBuy22,576C$7.21C$162,772.96
9/8/2016Douglas Robert LarsonDirectorSell800C$8.35C$6,680.00
3/29/2016Alfred D'souzaInsiderBuy2,000C$7.01C$14,014.00
3/24/2016Alfred D'souzaInsiderBuy3,100C$6.97C$21,591.50
3/24/2016Milt WakefieldDirectorSell2,000C$7.10C$14,200.00
3/23/2016Milt WakefieldDirectorSell2,000C$7.10C$14,200.00
3/21/2016Milt WakefieldDirectorSell4,000C$7.04C$28,160.00
3/16/2016Milt WakefieldDirectorSell2,000C$6.87C$13,740.00
3/9/2016Milt WakefieldDirectorSell4,000C$6.94C$27,776.00
6/17/2015Milt WakefieldDirectorSell4,000C$8.01C$32,040.00
6/15/2015Milt WakefieldDirectorSell4,000C$8.01C$32,040.00
(Data available from 1/1/2013 forward)


Biosyent (CVE RX) News Headlines

Equities Analysts Set Expectations for Biosyent Inc.s FY2017 Earnings (RX)Equities Analysts Set Expectations for Biosyent Inc.'s FY2017 Earnings (RX) - November 20 at 1:32 AM
Biosyent Inc. (RX) Set to Announce Earnings on WednesdayBiosyent Inc. (RX) Set to Announce Earnings on Wednesday - November 9 at 2:00 PM
Douglas Robert Larson Sells 1,300 Shares of Biosyent Inc. (RX) StockDouglas Robert Larson Sells 1,300 Shares of Biosyent Inc. (RX) Stock - September 18 at 4:18 PM
Insider Selling: Biosyent Inc. (RX) Director Sells 1,500 Shares of StockInsider Selling: Biosyent Inc. (RX) Director Sells 1,500 Shares of Stock - September 15 at 8:50 PM
Cormark Brokers Lift Earnings Estimates for Biosyent Inc. (RX)Cormark Brokers Lift Earnings Estimates for Biosyent Inc. (RX) - August 18 at 7:32 AM
BioSyent Releases Q2 and H1 2017 Results - CORRECTIONBioSyent Releases Q2 and H1 2017 Results - CORRECTION - August 16 at 3:58 PM
Biosyent Inc. (CVE:RX) Scheduled to Post Quarterly Earnings on ThursdayBiosyent Inc. (CVE:RX) Scheduled to Post Quarterly Earnings on Thursday - August 3 at 7:10 AM
FeraMAX(R) Named #1 by Canadian Physicians and Pharmacists for Second Consecutive YearFeraMAX(R) Named #1 by Canadian Physicians and Pharmacists for Second Consecutive Year - May 1 at 6:55 PM
BioSyent Announces Sale of Shares - BenzingaBioSyent Announces Sale of Shares - Benzinga - December 13 at 8:22 AM
Short Week in U.S. for ThanksgivingShort Week in U.S. for Thanksgiving - November 18 at 6:53 PM
BioSyent to Present at Upcoming Investor ConferencesBioSyent to Present at Upcoming Investor Conferences - April 7 at 1:23 PM

SEC Filings

Biosyent (CVE:RX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Biosyent (CVE RX) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.